SCHEMBL5362273

SCHEMBL5362273

O=CCCN1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2561862 0.89 SIGMAR1 (0.46)
SCHEMBL3244591 0.88
SCHEMBL678885 0.88
SCHEMBL3955804 0.87 ALDH1A1 (0.43)
SCHEMBL2552869 0.87 ALDH1A1 (0.38)
SCHEMBL3950976 0.87 ALDH1A1 (0.46)
Hydrochloric Acid SCHEMBL5552777 0.86 HRH3 (0.42)
SCHEMBL947690 0.86 HRH3 (0.48)
SCHEMBL29956822 0.86 HRH3 (0.48)
SCHEMBL5807819 0.86 HRH3 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127168-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION NEW YORK BLOOD CENTER, INC. 2025-04-24 US disclosed
US-20250049031-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION NEW YORK BLOOD CENTER, INC. 2025-02-13 US disclosed
US-20210227827-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION NEW YORK BLOOD CENTER, INC. 2021-07-29 US disclosed
CN-112996545-A Methods for pathogen, microbial and parasitic inactivation 萨塔制药公司 2021-06-18 CN disclosed
EP-3829656-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION Zata Pharmaceuticals Inc. (US) 2021-06-09 EP disclosed
US-10738005-B2 Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same ZATA PHARMACEUTICALS, INC. (US) 2020-08-11 US disclosed
US-10738005-B2 Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same ZATA PHARMACEUTICALS, INC. (US) 2020-08-11 US disclosed
WO-2020023881-A1 METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATION ZATA PHARMACEUTICALS, INC. (US) 2020-01-30 WO disclosed
US-20190106386-A1 AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME NEW YORK BLOOD CENTER, INC. 2019-04-11 US disclosed
US-20190106386-A1 AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME NEW YORK BLOOD CENTER, INC. 2019-04-11 US disclosed
US-20160289182-A1 AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME NEW YORK BLOOD CENTER, INC. 2016-10-06 US disclosed
WO-2015073622-A1 AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES COMPRISING THE SAME ZATA PHARMACEUTICALS, INC. (US) 2015-05-21 WO disclosed
EP-1867633-A1 Polyamine analogues as therapeutic and diagnostic agents MediQuest Therapeutics, Inc. (US) 2007-12-19 EP disclosed
US-7208528-B1 Polyamine analogues as therapeutic and diagnostic agents MEDIQUEST THERAPEUTICS, INC. (US) 2007-04-24 US disclosed
US-7160923-B1 Polyamine analogues as therapeutic and diagnostic agents MEDIQUEST THERAPEUTICS, INC. (US) 2007-01-09 US disclosed
EP-1085011-A1 Novel polyamine analogues as therapeutic and diagnostic agents ORIDIGM CORPORATION (US) 2001-03-21 EP disclosed
US-6172261-B1 BIOSYNTHESIS USING CHAIN EXTENSION ORIDIGM CORPORATION 2001-01-09 US disclosed
EP-1001927-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 2000-05-24 EP disclosed
WO-1999003823-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 1999-01-28 WO disclosed
US-5612329-A INTERFERENCE WITH CELL GROWTH AND PROLIFERATION UNIVERSITY OF MARYLAND AT BALTIMORE (US) 1997-03-18 US disclosed